3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Lymphoma
3
Neoplasms
2
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Neuroepithelial
1
Neoplasms, Germ Cell and Embryonal
1
Microphthalmia, Isolated, with Coloboma 5
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Choroid Plexus Carcinoma
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Cyclophosphamide
260
fludarabine phosphate
163
Methotrexate
124
Rituximab
112
Cytarabine
109
Filgrastim
106
fludarabine
92
Busulfan
86
Peripheral Blood Stem Cell Transplantation
83
Etoposide
82
Vincristine
80
Radiotherapy
79
Tacrolimus
73
Mycophenolic Acid
72
Antilymphocyte Serum
68
Whole-Body Irradiation
66
Melphalan
63
Dexamethasone
63
Cyclosporine
58
Doxorubicin
51
Prednisone
44
Methylprednisolone
44
Alemtuzumab
44
Mercaptopurine
41
Granulocyte Colony-Stimulating Factor
40
pegaspargase
35
Daunorubicin
34
Clofarabine
33
Thiotepa
31
Asparaginase
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
ribociclib
×
Lymphoid
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts